This study examines how Paris polyphylla can be used to treat Tongue Squamous Cell Carcinoma by targeting specific molecular mechanisms, providing a potential new treatment option for this common form of oral cancer.
ATO used to treat leukemia causes cardiac fibrosis through EndMT. DIO from Paris polyphylla may prevent this, showing potential for protecting heart health. Worth investigating further for cardiovascular therapy.
Researchers predicted targets and mechanisms of Polyphyllin for treating gastric cancer using Paris polyphylla rhizomes. Important for understanding traditional Chinese medicine and developing new GC treatments.
Scientists studied the potential anti-inflammatory and anticancer properties of Paris polyphylla Sm. rhizome, supporting traditional medicinal uses. This research could lead to the development of new treatments for various conditions.
Researchers studied the potential of a medicinal plant containing saponins to treat acne, due to antibiotic resistance. Saponins have antibacterial, anti-inflammatory, and antioxidant effects, making them promising for acne treatment.
Polyphyllin I (PPI), from Paris polyphylla, exhibits strong cytotoxicity on AML cells via ferroptosis induction. PPI targets PI3K/SREBP-1/SCD1 axis and triggers lipid peroxidation, with potential to enhance erastin-induced ferroptosis. PPI is a PI3K inhibitor, inhibits tumor progression, and prolongs survival in mice.
Scientists discovered five new compounds, parispolyosides A, E, and B-D, from the rhizome of Paris polyphylla var. chinensis. These compounds showed potential inhibitory effects on NO production and HepG2 cells. Molecular docking analysis suggested their mechanism of action on iNOS protein.
Paris polyphylla, a Chinese medicine, has been used to treat inflammation and pain. The main active component, Rhizoma Paridis saponins (RPS), has strong pain-relieving properties. You should care because RPS could potentially be used as an effective analgesic in medical treatments.
Researchers discovered enzymes in a medicinal plant that produce bioactive compounds. They found that these enzymes are versatile and generated new compounds, including a potential antifungal agent.
A new virus, PpCMV, was found in a plant in China. It has a genome of 6384 nucleotides and contains two open reading frames. Phylogenetic analysis shows it is closely related to two other viruses. This is the first report of PpCMV's complete genome sequence in China.
The study analyzed the heavy metal content and saponins in a Chinese medicinal plant (var.) used for centuries. They found that high heavy metal content reduced the anti-breast cancer activity. Controlling heavy metal content is important in cultivating var. for medicinal purposes.
Researchers investigated the effects of Polyphyllin II (PPII), a compound from Paris polyphylla, on autophagy-lysosome dysfunction in cancer. PPII showed potential antitumor activity, making it relevant for potential therapeutic interventions.
Paris polyphylla saponin II (PPII) inhibits tumor angiogenesis, but its mechanism is unknown. This study found that PPII increases autophagy in HUVEC cells through the PI3K/AKT/mTOR pathway, thereby inhibiting Hela cell proliferation, invasion, and migration. Care because PPII could potentially be used to treat cervical cancer.
Scientists discovered five new saponins from Paris polyphylla var. stenophylla. One of the compounds showed potential inhibitory effect on three glioma cell lines.
The researchers studied the chemical compositions of the aerial parts of Paris polyphylla var. chinensis and identified five new compounds. This research is important for the comprehensive utilization and development of waste parts of the plant.
The researchers studied the effects of a compound called Polyphyllin I (PPI) on castration-resistant prostate cancer cells. PPI showed potential as a treatment and the study explored its mechanism of action.
The study optimized the cultivation technique for callus suspension of the Smith (Melanthiaceae) plant. It found that 0.5 μM TDZ resulted in the maximum callus biomass, while 50 μM MeJA showed significant phenolic content and antioxidant activity. The research has commercial implications for the pharmaceutical and nutraceutical sectors.
Polyphyllin VII (PPVII), a compound found in Paris polyphylla, can inhibit gastric cancer (GC) by inducing autophagy-mediated ferroptosis. PPVII activates the ULK1 pathway, inhibits the activity of the protein TOPK, and stabilizes its inactive form, suggesting PPVII could be a potential treatment for GC.
Polyphyllin D (PD) from Paris polyphylla herb exhibits anticancer effects in triple-negative breast cancer via apoptosis induction and alterations in spliceosome function. NOMO2/3 may be a potential target of PD. Further validation is required.
This study shows that Paris polyphylla polysaccharide component 1 (PPPm-1) can improve learning and memory in aging mice. It works by reducing oxidative stress, regulating the cholinergic nervous system, enhancing long-term memory, and activating the Wnt/β-catenin signaling pathway.
A herbal remedy called Paris polyphylla has been used for centuries to treat convulsions, head shaking, tongue fiddling, and epilepsy. Recent studies suggest that this remedy's ability to improve learning and memory may be due to specific polysaccharides found in the plant. These polysaccharides are thought to influence important signaling pathways involved in brain function. The findings also suggest that Paris polyphylla could have a protective effect on the nervous system. This research could have implications for the development of new treatments for neurological disorders.
This study explores the potential of Polyphyllin VII (PP7), a compound derived from a traditional Chinese herb, in treating bone destruction caused by metastatic breast cancer. The researchers found that administering PP7 significantly reduced osteolysis induced by breast cancer cells in mice. PP7 also inhibited the formation of osteoclasts, reduced bone resorption, and promoted the formation of osteoblasts. The study suggests that PP7 has the potential to be a safe and effective treatment for preventing and treating bone destruction in breast cancer patients with bone metastases.